Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
Feeds
54689 items (54689 unread) in 74 feeds
Acinar Cell Carcinoma
(336 unread)
Acinic Cell Carcinoma
(249 unread)
Adenoid Cystic Carcinoma
(1043 unread)
Adrenal Gland Cancer
(4887 unread)
Ampulla Of Vater
(1142 unread)
Anal Cancer
(5337 unread)
Angiosarcoma
(1622 unread)
Appendix Cancer
(781 unread)
Bile Duct Cancer
(7021 unread)
Brain and CNS
(7255 unread)
Carcinoid
(2316 unread)
Endocrine/Neuroendocrine
(5767 unread)
Gall Bladder Cancer
(2526 unread)
Hemangioendothelioma
(787 unread)
Hepatoblastoma
(761 unread)
Pancreas
(751 unread)
Phyllodes
(416 unread)
PMP and Mucinous Tumors
(472 unread)
Rhabdomyosarcoma
(2157 unread)
Sarcoma
(9063 unread)
Google - Appendix Cancer
-
Loxo Oncology to Seek FDA Approval for Pan-Cancer Drug in Patients with TRK Fusions - GenomeWeb
Posted: June 3rd, 2017, 5:00am GMT
Loxo Oncology to Seek FDA Approval for Pan-Cancer Drug in Patients with TRK Fusions GenomeWeb